Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) February 17, 2005

 


 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-32085   36-4392754

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

   

222 Merchandise Mart Plaza, Suite 2024,

Chicago, IL 60654

   
         

 

Registrant’s telephone number, including area code (312) 506-1200.

 

N/A

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 2.02. Results of Operations and Financial Condition.

 

On February 17, 2005, the registrant announced its earnings for the quarter and year ended December 31, 2004. Further details are described in the press release issued by the registrant on February 17, 2005, and furnished as Exhibit 99.1 hereto and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.

  

Description of Exhibit


99.1    Press release issued February 17, 2005

 

2


SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: February 17, 2005

 

By:

 

/s/ William J. Davis


       

William J. Davis

       

Chief Financial Officer


INDEX TO EXHIBITS

 

Exhibit
Number


 

Description


99.1   Press Release issued February 17, 2005
Press Release

Exhibit 99.1

 

Allscripts Healthcare Solutions Contact:

Dan Michelson

Chief Marketing Officer

312-506-1217

dan.michelson@allscripts.com

 

Bill Davis

Chief Financial Officer

312-506-1211

bill.davis@allscripts.com

 

 

FOR IMMEDIATE RELEASE

 

Allscripts Reports Record Results for 2004

 

Clinical Software Sales Exceed $25 Million in Fourth Quarter

 

CHICAGO, IL – February 17, 2005 – Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, announced its results for the three months and year ended December 31, 2004.

 

Total revenue for the three months ended December 31, 2004, was $26.3 million, compared to $23.7 million for the three months ended December 31, 2003. Revenue from clinical software and information services for the three months ended December 31, 2004, was $17.0 million, increasing 44% over the comparable period last year.

 

Net income for the three months ended December 31, 2004, of $1.4 million or $0.03 per diluted share, compares to a net income of $0.1 million or $0.00 per share, for the same period last year.

 

As of December 31, 2004, the Company had cash and marketable securities of $128.2 million.

 

“2004 was an exceptional year for Allscripts,” commented Glen Tullman, Chief Executive Officer of Allscripts. “Providing physicians with the information they need and connectivity to key healthcare stakeholders offers an opportunity to transform the way healthcare is delivered. The demand for our products has never been stronger.”

 

Total revenue for the twelve months ended December 31, 2004, was $100.8 million, compared to $85.8 million for the twelve months ended December 31, 2003. Revenue from clinical software and information services for the twelve months ended December 31, 2004, was $56.0 million, increasing 41% over the comparable period last year.

 

Net income for the year ended December 31, 2004, of $3.1 million or $0.07 per diluted share, compares to a net loss of $5.0 million or $0.13 loss per share, for the year ended December 31, 2003.

 

Allscripts will conduct a conference call on Thursday, February 17, 2005, at 4:30 PM eastern time. The conference call can be accessed by dialing 1-800-374-0526, or via the Internet at www.allscripts.com. A recording of the conference call will be available for review through March 3, 2005, at www.allscripts.com or by calling 1-800-642-1687, ID # 3686443.


About Allscripts Healthcare Solutions

 

Allscripts Healthcare Solutions (Allscripts) is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The Company’s business groups provide unique solutions that inform, connect, and transform healthcare. The Clinical Solutions Group’s award-winning clinical software applications include electronic health record (EHR), e-prescribing and document imaging solutions. Additionally, Allscripts provides healthcare product education and connectivity solutions for physicians and patients through its Physicians Interactive Group and medication fulfillment services through its Medication Services Group. Visit Allscripts on the Web at www.allscripts.com.

 

 

This announcement may contain forward-looking statements about Allscripts Healthcare Solutions that involve risks and uncertainties. These statements are developed by combining currently available information with Allscripts beliefs and assumptions. Forward-looking statements do not guarantee future performance. Because Allscripts cannot predict all of the risks and uncertainties that may affect it, or control the ones it does predict, Allscripts’ actual results may be materially different from the results expressed in its forward-looking statements. For a more complete discussion of the risks, uncertainties and assumptions that may affect Allscripts, see the Company’s 2003 Annual Report on Form 10-K, available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov.


Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Balance Sheets

(amounts in thousands)

(Unaudited)

 

Assets    December 31,
2004


   December 31,
2003


Current assets

             

Cash and cash equivalents

   $ 16,972    $ 13,336

Marketable securities

     22,796      3,435

Accounts receivable, net

     21,382      18,219

Other receivables

     627      237

Inventories

     2,372      3,249

Prepaid expenses and other current assets

     3,571      3,863
    

  

Total current assets

     67,720      42,339

Long-term marketable securities

     88,471      34,538

Software development costs, net

     6,270      4,040

Fixed assets, net

     2,366      2,237

Intangible assets, net

     24,546      26,359

Other assets

     4,804      879
    

  

Total assets

   $ 194,177    $ 110,392
    

  

Liabilities and Stockholders’ Equity          

Current liabilities

             

Accounts payable

   $ 5,981    $ 6,082

Accrued expenses

     12,218      7,906

Deferred revenue

     14,607      10,959
    

  

Total current liabilities

     32,806      24,947

Long-term debt

     82,500      —  

Other liabilities

     178      2,055
    

  

Total liabilities

     115,484      27,002

Stockholders’ equity

     78,693      83,390
    

  

Total liabilities and stockholders’ equity

   $ 194,177    $ 110,392
    

  

 

Stockholders’ equity includes ($11,250) of treasury shares as of December 31, 2004 and $0 as of December 31, 2003.


Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Statements of Operations

(amounts in thousands, except per-share amounts)

(Unaudited)

 

     Three Months Ended
December 31,
    For the Year Ended
December 31,
 
     2004

    2003

    2004

    2003

 

Revenue:

                                

Prepackaged medications

   $ 9,342     $ 11,894     $ 44,733     $ 46,172  

Software and related services

     14,306       8,318       44,121       28,366  

Information services

     2,665       3,441       11,916       11,303  
    


 


 


 


Total revenue

     26,313       23,653       100,770       85,841  

Cost of revenue:

                                

Prepackaged medications

     7,317       9,460       35,744       36,303  

Software and related services

     5,154       3,264       15,858       14,050  

Information services

     1,506       1,617       6,520       4,816  
    


 


 


 


Total cost of revenue

     13,977       14,341       58,122       55,169  
    


 


 


 


Gross profit

     12,336       9,312       42,648       30,672  

Operating expenses:

                                

Selling, general and administrative expenses

     10,337       9,084       37,653       36,058  

Amortization of intangibles

     441       388       1,752       951  
    


 


 


 


Income (loss) from operations

     1,558       (160 )     3,243       (6,337 )

Interest expense

     (884 )     —         (1,717 )     —    

Interest income

     802       241       1,675       1,384  

Other income (expense), net

     (73 )     35       (93 )     (26 )
    


 


 


 


Income (loss) before income taxes

     1,403       116       3,108       (4,979 )

Income taxes

     —         —         —         —    
    


 


 


 


Net income (loss)

   $ 1,403     $ 116     $ 3,108     ($ 4,979 )
    


 


 


 


Net income (loss) per share—basic

   $ 0.04     $ 0.00     $ 0.08     ($ 0.13 )
    


 


 


 


Net income (loss) per share—diluted

   $ 0.03     $ 0.00     $ 0.07     ($ 0.13 )
    


 


 


 


Weighted average shares of common stock outstanding used in computing basic net income (loss) per share

     38,484       38,956       38,979       38,621  
    


 


 


 


Weighted average shares of common stock outstanding used in computing diluted net income (loss) per share

     41,439       40,700       41,592       38,621